Azitra, Inc. will participate in the H.C. Wainwright Annual Conference, where it will present key developments in its biopharmaceutical pipeline and innovative research.

Azitra, Inc. has successfully regained compliance with NYSE American standards, allowing it to focus on advancing innovative treatments in dermatology and cosmetics.

Azitra, Inc., a clinical stage biopharmaceutical company, announces promising Q2 2026 results alongside significant business updates focusing on precision dermatology.

Discover the promising breakthroughs from Azitra, Inc. in their ATR-COSF program that highlights enhanced skin elasticity and anti-wrinkle effects.

ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredient Ex vivo data successfully showed controlled distribution of...

Azitra (NYSE American: AZTR) reported new ex vivo human skin data for its ATR-COSF cosmetic program, a supernatant from engineered S. epidermidis that secretes a recombinant human filaggrin domain (rHDfilaggrin). Multiple-dose experiments in TH2-stimulated healthy skin explants showed increased rHDfilaggrin penetration through the stratum corneum into the stratum granulosum versus prior single-dose work, with higher concentrations when formulated as a 2% lyophilized hydrogel compared with concentrated supernatant alone.In a second ex vivo model using defatted human skin, ATR-COSF hydrogels containing 0.09–7.5% (w/w) supernatant increased elasticity in a dose-dependent manner, from 1.6-fold to 4.4-fold. A 0.28% (w/w) formulation restored elasticity to levels historically observed in healthy skin, and a 0.3% (w/w) sample showed about twice the elasticity of placebo. Safety testing found the 2% supernatant hydrogel non-irritating and non-corrosive to skin and eyes, supporting its potential as a high-value anti-wrinkle cosmetic ingredient, according to Azitra.

Azitra (NYSE American: AZTR) CEO outlined a strategic reorientation toward programs with nearer-term value milestones, backed by a March 2026 financing of $10.5 million plus up to $21 million from warrant exercises.Key moves include launching the ATR-COSF cosmetic filaggrin initiative, new recombinant protein programs, continued ATR-04 enrollment, and pausing ATR-12 enrollment to conserve capital, with multiple potential partnering or commercialization opportunities from 2026 onward.